Recce Pharmaceuticals (RCE.AX) Earnings Analysis
Recce Pharmaceuticals (RCE.AX) next reports earnings on 2026-08-28. Trailing P/E -3.18.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RCE.AX next report earnings?
| Next earnings date | 2026-08-28 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
RCE.AX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-27 | -0.0573 AUD | n/a | n/a | n/a |
| 2024-10-31 | -0.05 AUD | n/a | n/a | n/a |
RCE.AX valuation and analyst view
| Trailing P/E | -3.18 |
|---|---|
| Trailing EPS | -0.10463 AUD |
| Price / book | -5.59 |
| Dividend yield | 0.00% |
| Market cap | 0.10B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Recce Pharmaceuticals (RCE.AX)'s next earnings date?
Recce Pharmaceuticals is next scheduled to report on 2026-08-28.
Did RCE.AX beat earnings last quarter?
Consensus estimate data was not available for RCE.AX's 2026-02-27 report.
What is RCE.AX's current P/E ratio and EPS?
RCE.AX trades at a trailing P/E of -3.18 on trailing EPS of -0.1046348047164843 AUD.
What do analysts rate RCE.AX?
RCE.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.